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To guide the design of a nation-wide cohort study of chronic
kidney disease in children, we determined how iohexol
plasma disappearance curves could be used in children to
measure glomerular filtration rate (GFR). Iohexol (5 ml) was
administered intravenously and blood samples were
obtained at 10, 20, 30, 60, 120, 240, 300, and 360 min after
injection (N¼ 29) and assayed by high performance liquid
chromatography. Four urines were also collected following
the injection. Intra-assay coefficient of variation (CV) in serum
was 1.3% at 100 mg/l, 2.6% at 15 mg/l, and 3.4% for duplicate
unknowns. GFR(9) was computed from iohexol dose and area
under the nine-point blood disappearance curve, using
double exponential modeling. Only 2.8% of 254 data points
deviated by 43 CV from the curves. GFR(4) calculated from
10, 30, 120, and 300 min points correlated well with GFR(9)
(r¼ 0.999) and showed no bias (means7s.d. of GFR(9) and
GFR(4)¼ 59.3736.3 and 59.4736.0 ml/min per 1.73 m2).
Relationship of GFR(9) and one-compartment GFR followed
quadratic equation as previously reported by Brochner-
Mortensen, allowing GFR to be calculated from 120 and
300 min points. This GFR(2) correlated well with GFR(9)
(r¼ 0.986). Estimated GFR from Schwartz height/creatinine
formula correlated with GFR(9)(r¼ 0.934) but overestimated
GFR by 12.2 ml/min per 1.73 m2. Urine iohexol clearance was
poorly correlated (r¼ 0.770) with GFR(9) owing to variability
in urine collections (median CV¼ 24%). GFR can be measured
accurately using four-point iohexol plasma disappearance (in
most cases, two points suffice); estimated GFR and urinary
clearances are less useful.
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Glomerular filtration rate (GFR) is the most useful indicator
of kidney function and progression of kidney disease. In
current practice, GFR is generally determined by creatinine
clearance or estimated by an equation, that takes into
consideration serum creatinine, age, race, and gender in
adults,1 and serum creatinine, height, and an empirical
constant in children.2 However, creatinine clearance has
limited accuracy owing to the secretion of creatinine by the
renal proximal tubules.3 When there is a clinical need to accu-
rately determine GFR, as for planning cancer chemotherapy
with nephrotoxic agents or in staging chronic kidney disease
(CKiD) in preparation for renal replacement therapy, it may
be necessary to utilize a more definitive measurement of
GFR. Similarly, in planning for clinical trials or observational
research studies in chronic kidney disease, an accurate
measure of GFR is required. We sought to determine the
feasibility, accuracy, and precision of the plasma disappear-
ance of iohexol as the measure of GFR in a nation-wide
cohort study of chronic kidney disease in children. The
primary aim of the CKiD study is to define risk factors for
decline in GFR in children, and to examine the effect of GFR
decline on cardiovascular morbidity, growth, cognition, and
behavior.
The gold standard for measuring GFR is the standard
inulin clearance, performed by loading and continuously
infusing inulin and collecting timed urine samples via an
indwelling bladder catheter.4 Such a method requires
extensive technical assistance, the use of a bladder catheter,
and a difficult chemical assay. Moreover, inulin is no longer
readily available. Accurate collection of urine without bladder
catheterization is very difficult in children.
Alternatively, radioactive agents such as 51Cr-EDTA,
99mTc-DTPA, and 125I or 131I-iothalamate have been used
as surrogate markers of GFR. These agents are generally given
by a single injection bolus and the disappearance from the
blood is monitored (plasma clearance). (It should be noted
that we refer to plasma disappearance curve despite the fact
that most assays are performed in sera from the subjects. The
concept of disappearance from the plasma relates to the fact
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that GFR is dependent on renal plasma flow in vivo.). From
the dose and the area under the curve as a function of time, a
determination of GFR can be obtained. Conventional renal
clearances are also performed, particularly using iothalamate.
However, there are problems with each of these agents: 51Cr-
EDTA, although an excellent marker, is not available in the
USA; the renal handling of 99mTc-DTPA can vary with
commercial source;5 and iothalamate is readily secreted by
the kidney.6 Thus, none of these markers can adequately
replace the standard inulin clearance. Moreover, the use of
radioactive substances and bladder catheterization are strong
deterrents to study subject participation, and were therefore
deemed unsuitable when planning the CKiD study.
In Scandinavia, iohexol has been used as a satisfactory
marker of GFR in adults7,8 and children.9,10 Iohexol is readily
available as a safe non-ionic low-osmolar contrast agent of
molecular weight 821 Da (OmnipaqueTM) that is used
intravenously for radiologic procedures even in the presence
of renal disease. It is not secreted, metabolized, or reabsorbed
by the kidney.7,11,12 Iohexol diffuses into the extracellular
space, but has less than 2% plasma protein binding,7,13 and is
eliminated exclusively without metabolism by the kid-
neys.7,11,12 Extrarenal elimination of iohexol in a setting of
reduced GFR is negligible.14 Most studies indicate close
agreement between GFR (measured by inulin clearance) and
clearance of iohexol, measured as standard renal clearance or
plasma disappearance.11,12,15–17 There is also a very good
correlation between iohexol clearance and 51Cr-EDTA plasma
clearance.8
Iohexol can be measured in deproteinized serum by high
performance liquid chromatography (HPLC), thereby ob-
viating the need for radioactivity. There are two isomers,
both of which are handled similarly by the body.8,11 In
practice, the major peak, eluting at about 5 min, is used for
plasma disappearance curves. The single-injection approach
is technically less demanding than a constant infusion with
urine collection and can be accomplished with less technical
assistance.
Accordingly, we explored whether iohexol could serve as
the GFR marker in the CKiD study. The recruitment goal of
this prospective study is to enroll over 500 children and
adolescents with mild to moderate chronic kidney disease. By
design, GFR is to be measured three times over 5 years of
follow-up. We addressed four specific objectives in this pilot
study. First, we determined the appropriateness of the two-
compartment (double exponential) model for iohexol
disappearance from the blood and calculation of GFR and
whether it could be approximated by a pair of data points
determining each exponential (i.e., four points in total).
Second, we investigated whether a one-compartment model
of iohexol disappearance yields a satisfactory determination
of GFR. Third, we examined whether estimates of GFR
(eGFR) using the Schwartz height/creatinine formula2,18
could closely approximate iohexol GFR based on the double
exponential model. Fourth, we compared the two-compart-
ment GFR with the renal clearance of iohexol using four
timed collections of urine obtained during the plasma
disappearance study.
RESULTS
Iohexol measurement
The intra-assay coefficient of variation (CV) for repeated
determinations of iohexol was 1.3% at 100 mg/l and 2.6% at
15 mg/l. The CV for duplicate unknowns was 3.4%.
Two-compartment GFR
The disappearance of iohexol from the blood can be
described by a double exponential curve, as seen by the plot
of iohexol concentration vs time (Figure 1a). Examination of
the logarithm of the iohexol concentrations permits linear
curve fitting of the slow (renal) curve (Figure 1b).
Subtraction of extrapolated early concentrations from the
initial concentrations up to 120 min generates the fast curve,
which is also linear on the log scale (Figure 1c). The
descriptive statistics of the 29 curves are shown in Table 1,
from which it is evident that the half-time of the slow curve
(169.9 min) was nearly 10 times longer than that of the fast
curve (19.7 min). In addition, the median area of the slow
curve (60.83 mg min/ml) was more than 10 times that of the
fast curve (4.93 mg min/ml).
A scatterplot of the areas of the slow and fast components
for the 29 subjects showed no correlation between the area of
the fast component and that of the slow component
(r¼ 0.17). The 29 values of GFR(9) ranged from 16.5 to
162.3 ml/min per 1.73 m2, with four above 100 ml/min per
1.73 m2, two of which were provided by first and senior
authors (GJS and AM) who initiated the study. The median
GFR was 56.7 ml/min per 1.73 m2, with the first and third
quartiles being 36.5 and 71.7 ml/min per 1.73 m2 (Table 1).
From 263 sample points, there were nine low and outlying
values (3.4%), which were excluded because they were
smaller than the subsequent value. Eliminating these revealed
that the goodness of fit was excellent, with only 2.8% of the
remaining 254 values deviating by more than 3 CVs from the
curves.
Figure 2a shows that GFR(4) was extremely well correlated
(R¼ 0.999) with GFR(9). Bland–Altman analysis showed that
both the standard deviations (s.d.) and the computed bias
were not significantly different between GFR(4) and GFR(9)
(Figure 2b). The means and s.d. of GFR(9) and GFR(4) were
practically identical (GFR(9): 59.3736.3 and GFR(4):
59.4736.0).
One-compartment GFR
Figure 3 shows the scatterplot of the GFR based only on the
slow component from the serum concentrations between 120
and 360 min and the GFR(9). This one-compartment
clearance, also called a slope–intercept clearance, was well
correlated to the two-compartment model. It is evident that
the slope–intercept clearance overestimates the two-compart-
ment model GFR, and this overestimate becomes progres-
sively larger at higher GFR. Moreover, the curve fitting of a
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linear and squared term was excellent, and the equation was
0:9950GFRðAÞ  0:001159ðGFRðAÞÞ2
whose coefficients are very similar to those originally
published by Brochner-Mortensen.19 GFR(2) was also
calculated solely from the slow (renal) component using
the points at 120 and 300 min for the slow component in
conjunction with the above equation. The GFR(2) correla-
ted well with that from the 9-point GFR(9) (r¼ 0.986)
(Figure 4a). Bland–Altman analysis showed that both the s.d.
and the computed bias were not significantly different
between the two-compartment and one-compartment GFR
values (Figure 4b). One data point was far below zero,
indicating significant inaccuracy in the two-point determina-
tion of the slow component of that study. This was because
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Figure 1 | Iohexol disappearance curves from the blood. (a) Plot of iohexol disappearance vs time (min) on the x axis. (b) Logarithm of
iohexol disappearance, showing the linear fitting of the slow (renal) curve to the points from 120 to 360 min. (c) Logarithm of iohexol
disappearance, showing the linear fitting of the fast curve to the points from 10 to 60 min. This fast iohexol disappearance curve was obtained
by subtracting the slow curve from the overall disappearance curve, thus revealing the linear fit of the fast curve.
Table 1 | Descriptive statistics of study population and
characteristics of iohexol plasma disappearance curves
(N=29)
Variable Median 1st quartile 3rd quartile
Age (years) 14 12 18
Gender 59% male — —
Height (cm) 156.2 145.8 168.0
Weight (kg) 58.4 43.2 75.4
BSA (m2) 1.661 1.313 1.880
Serum creatinine (mg/dl)a 1.5 1.1 2.2
eGFR (ml/min per 1.73 m2) 66.0 43.4 81.0
Iohexol dose (I, mg) 3185.0 3175.4 3223.5
Slow component
Intercept (mg/ml)=exp A 0.245 0.169 0.318
Half-time (min)=log 2/a 169.9 130.2 240.2
Area (mg min/ml)=exp A/a 60.83 39.68 97.53
Fast component
Intercept (mg/ml)=exp B 0.169 0.116 0.238
Half-time (min)=log 2/b 19.7 16.5 23.4
Area (mg min/ml)=exp B/b 4.93 3.44 6.14
Total area=exp A/a+exp B/b 65.87 44.30 100.72
GFR (ml/min per 1.73 m2)b 56.7 36.5 71.7
BSA, body surface area; eGFR, estimated GFR from Schwartz formula; GFR,
glomerular filtration rate.
aValues missing from the two adults (N=27).
bGFR was calculated from (I/total area) 1.73/BSA.
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Figure 2 | Two-component GFR comparing nine points against
four points. (a) Scatterplot of GFR values computed from nine-point
iohexol disappearance (x axis) vs the four-point GFR computed from
samples taken at 10, 30, 120, and 300 min (y axis), with line of perfect
agreement as reference, showing excellent correlation (r¼ 0.999).
(b) Bland–Altman plot of GFRs computed from the nine-point GFR
(GFR(9)) vs that from the four-point GFR (GFR(4)). The agreement was
excellent with no bias or trend towards changing variability at lower
GFR values.
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the concentration at 120 min was unduly low and there were
no other points to compensate for this bias, as there is
possibly in the presence of four and certainly in the presence
of nine points. The two patients with nephrotic syndrome
were not outliers on these plots, indicating that edema and
ascites fluid did not alter the observed agreement.
Estimated GFR
GFR estimated from the Schwartz formula was also well
correlated with the two-compartment GFR (r¼ 0.934)
(Figure 5a); however, there was a significant positive bias of
12.22 ml/min per 1.73 m2, meaning that the eGFR over-
estimated true GFR. Furthermore, the bias was not
significantly different in the four studies performed using
Jaffe creatinines. The two adults were not included in this
analysis.
Urine GFR
Urine iohexol clearances did not correlate as well as the other
clearances with the two-compartment GFR (r¼ 0.770)
(Figure 5b). This was owing primarily to large variability in
the urine collections. The median CV of the four urine
clearances was 24% in the 29 subjects. In addition, the urine
clearance significantly underestimated the two-compartment
GFR by 13.95 ml/min per 1.73 m2. One sample showed an
underestimation of 97 ml/min per 1.73 m2 probably reflecting
inadequate bladder emptying in a 3-year-old boy. Elimi-
nation of that sample yielded an average underestimation of
11.1 ml/min per 1.73 m2.
DISCUSSION
Use of plasma disappearance for determination of
two-compartment GFR
The national CKiD study requires an accurate determination
of GFR so that small changes over time can be reliably
detected. Whereas inulin is the gold standard for measuring
GFR,20 there are major limitations to using this agent.21,22
This has led clinicians to use the plasma disappearance of
alternative markers, which diffuse more readily into the
extracellular fluids. 51Cr-EDTA (mw 292 Da) serves as an
excellent marker for GFR,23–25 particularly in the UK,26 but
this agent is not available in the USA.
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Figure 3 | One-component GFR. Correlation of GFR values
computed from nine-point iohexol disappearance (y axis) vs GFR
computed solely from the iohexol dose divided by the area under the
curve of the slow (renal) component that was determined from five
points between 120 and 300 min. The one-compartment model
progressively underestimated GFR from the two-compartment
model.
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Figure 4 | Two-component GFR based on nine points and one
component GFR based on two points (GFR(2)). (a) Regression
of GFR values computed from nine-point iohexol disappearance
((GFR(9)) vs those computed from the one compartment using the
coefficients for a linear and squared term determined from the
curve-fitting analysis, which are similar to those used previously by
Brochner-Mortensen.19 The correlation was highly significant at 0.970.
(b) Bland–Altman plot of GFRs computed from the two compartment
model (GFR(9)) vs that from the two-point GFR (GFR(2)). With one
exception, the agreement was excellent with virtually no bias and no
trend towards changing variability at lower GFR values.
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Figure 5 | Comparison of two-compartment GFR (GFR(9)) vs
estimated GFR from Schwartz formula and standard urine
iohexol clearance. (a) Regression of GFR estimated from Schwartz
formula (eGFR) vs two compartment GFR(9), showing an excellent
correlation coefficient of 0.934. Whereas the correlation was high, the
eGFR consistently overestimated GFR(9) by an average of 12.2 ml/min
per 1.73 m2. The variability, while great, did not change as a function
of GFR. (b) Regression of renal clearance of iohexol (urine GFR) vs the
two-compartment GFR(9), showing a weaker correlation coefficient of
0.770. There appeared to be a significant amount of variability at all
levels of GFR, and the renal clearance underestimated GFR(9) by
13.95 ml/min per 1.73 m2.
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Iothalamate (mw 637 Da) is available as 125I-iothalamate
or as a non-radioactive agent. However, iothalamate is
actively secreted by renal proximal tubular cells6 and its
clearance exceeds that of inulin or 51Cr-EDTA.6,27 Thus, this
marker is not ideal for measuring GFR, particularly in
subjects with reduced kidney function.
Validation of iohexol as a marker for determination of GFR
Based on the experience in Scandinavia, iohexol may be the
best alternative available to measure GFR. Iohexol is
eliminated exclusively via the kidneys12,14 and can be
completely recovered from the urine within 12–24 h.12,13
Extrarenal clearance of iohexol does not exceed 2 ml/min per
1.73 m2.28 As a non-ionic contrast agent, iohexol causes many
fewer adverse reactions than does conventional contrast
medium.13,15 Because the molecular weight of iohexol
(821 Da) is somewhat larger than those of the radioactive
markers, and the normal elimination half-time is 1.5–2 h,12,13
the time interval between injection and the final point in
plasma sampling should be at least 3 h9 and longer for
children with reduced GFR.
Brandstrom et al.29 examined simultaneous single-injec-
tion studies of 51Cr-EDTA and iohexol in 49 adults and
found that single-compartment GFRs were highly correlated
(r¼ 0.922), and the slope and intercept of the regression were
not different from 1 and zero, respectively. These data29 plus
the preceding and comparable study of Krutzen et al.13 in 42
patients (r¼ 0.983) indicate, over a wide range of GFR, that
both methods give equivalent results with a mean difference
of less than 1 ml/min.
In addition to the excellent agreement of iohexol and 51Cr-
EDTA plasma clearances, there is also excellent agreement
between the iohexol and inulin clearances. Gaspari et al.11
have shown in 41 patients excellent agreement (r¼ 0.982)
between iohexol plasma clearance and inulin renal clearance,
and Bland–Altman analysis revealed the mean difference
between the two methods to be 1.02 ml/min per 1.73 m2.
Brown and O’Reilly15 showed in 30 patients an excellent
agreement between iohexol plasma clearance and renal inulin
clearance (r¼ 0.983) with a mean ratio not significantly
different from 1. Similarly, Erley et al.16 showed an excellent
agreement in ICU patients between constant inulin infusion
clearance and iohexol plasma clearance (r¼ 0.980). In
children, Lindblad and Berg30 showed a good correlation
(r¼ 0.822) between iohexol slope clearance and renal inulin
clearance. The failure to show a better correlation might have
reflected insufficient time for equilibration of the blood
samples (1, 2, and 3 h after iohexol injection). (Immediately
after intravenous injection, the marker substance leaves the
plasma both by glomerular filtration and by diffusion into
the extravascular body fluid compartments. The amount
of marker substance excreted during this early phase (fast
curve) is ‘lost’ from the body fluids and thus a somewhat
smaller dose than injected is distributed in the body fluid
compartments. With time, the concentrations in plasma and
extravascular fluid equalize, and the plasma elimination
rate becomes constant (slow curve). However, because of
glomerular filtration, the concentration in the extracellular
fluid from then on remains somewhat higher than the plasma
concentration). In sum, iohexol plasma clearance appears
to yield results that are comparable to those obtained using
renal inulin clearance and plasma 51Cr-EDTA disappearance.
Indeed, some have suggested that iohexol is the new gold
standard measure of GFR.15,17
Plasma disappearance of iohexol to measure GFR
The GFR is calculated from the dose of iohexol divided by the
area under the plasma disappearance curve (AUC), fitted by a
double exponential equation. The two curves can be well
approximated by obtaining serum samples at 10, 30, 120, and
300 min, yielding nearly as accurate a measurement as that
obtained using the nine points over this time period (see
Figure 2). Moreover, for most routine clinical practices, GFR
can be satisfactorily estimated by using two blood samples to
determine the second exponential (slow, renal curve) in
conjunction with the Brochner-Mortensen equation, which
we showed here to be very consistent whether iohexol
(coefficients: 0.9950 and 0.001159; see Figure 3) or 51Cr-
EDTA (coefficients: 0.990778 and 0.001218 for adults;19
1.01 and 0.0017 for children31) are used. The agreement
with the coefficients generated by Brochner-Mortensen is
impressive, considering that the original study was performed
in adults and the GFR was determined by 51Cr-EDTA.
Furthermore, based on preliminary analysis of the first 68
children in the CKiD study, we continue to show excellent
agreement (i.e., no bias, same variances and correlation¼
0.997) between the GFR based on four points (at 10, 30, 120,
and 300 min) and the GFR based on two points (at 120 and
300 min). These additional data strengthen the conclusions
based on the pilot study (N¼ 29).
The agreement between two points and nine points in
the pilot study and of two points and four points in the
preliminary data of CKiD makes it conceivable that the
iohexol procedure can be simplified to two points. However,
if one uses only two points to measure the slow component,
the first of these should be taken no earlier than 2 h after
injection to avoid a contribution from the fast exponential.26
In addition, in children with decreased GFR, the subsequent
blood samples should be obtained not earlier than 5 h after
injection.
Our pilot study suggests that two points taken at 120 and
300 min after iohexol injection are adequate to determine
GFR. However, when using only two points, if one of them is
inaccurate, it will have a great impact on the determination of
GFR (see outlier in Figure 4). In contrast, when having four
points (e.g., at 10, 30, 120, and 300 min), not only have
we shown excellent agreement with the nine-point GFR (see
Figure 3), but four points allow for the use of crossvalidation
methods to make four concentrations mutually consistent.
These considerations allow us to recommend a non-radio-
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active iohexol-based approach with four points at 10, 30, 120,
and 300 min for the nation-wide cohort of children.
Whether or not in the future one simplifies the procedure
to utilize the one-compartment approach for all patients
depends on the effect of significant edema and ascites on this
relation, and this question will be addressed in the first year
of the national study. In the pilot study, two patients had
significant edema and ascites but the one-compartment GFR
was not altered by these physical findings.
Comparison with estimated GFR
Daily clinical practice requires a method for simple and
inexpensive yet accurate methods for evaluating GFR.
Whereas serum creatinine and estimating equations are
widely used in adults for this purpose, they have less utility in
pediatrics because of the maturational increase in serum
creatinine that occurs concurrently with the increment in
muscle mass.2,32 Since the 1970s, pediatric nephrologists have
utilized formulae based on patient height and serum
creatinine, because of the close relationship between height
and muscle mass.2,18,33 The formulae were initially developed
based on serum creatinine measured by a colorometric
reaction with alkaline picrate (Jaffe). More recently, serum
creatinine has been measured enzymatically2 and eGFR
formulas have not been generated using enzymatic creati-
nines. Because enzymatic creatinine determinations yield
smaller values than the Jaffe reaction, one would expect the
Schwartz-derived eGFR formulae to overestimate true GFR,
as seen in this pilot study.
Difficulties with urine collection to measure GFR
It is well known that collection of urine without bladder
catheters does not add significant accuracy to the clearance
estimate of GFR.34 Indeed, 24 h urines may vary by as much
as 10–15% from one day to another35,36 and this variability
limits the accuracy of renal clearances. Among children
with chronic kidney disease, many of whom have bladder
dysfunction (e.g., bladder dyssynergia, neurogenic bladder,
vesicoureteral reflux), variability in urinary clearances is
likely to be even larger than those seen in adult studies.
In our pilot study, the GFR determined from the renal
iohexol clearance was poorly correlated with true GFR
(r¼ 0.770), and the negative bias indicated that renal iohexol
clearance was less than plasma disappearance GFR. Although
one might conclude that there is non-renal elimination of
iohexol, previous studies have shown minimal non-renal
iohexol elimination.7,12,13,28 It is more likely that the negative
bias in the pilot study reflects inadequate bladder emptying.
Urologic problems, which occur in a large percentage of
children with chronic renal disease, may cause incomplete
bladder emptying and hence lead to inaccurate determina-
tions of GFR.
In summary, we have validated the use of iohexol plasma
disappearance as a useful measure of GFR in children.
Whereas the pilot study utilized the data from nine points
obtained during 6 h, we have shown that four points at 10,
30, 120, and 300 min suffice. Furthermore, in most cases, two
determinations along the slow curve would be adequate to
accurately determine GFR. The main caveat is to allow for
complete iohexol equilibration, which may require sampling
as late as 5 h after iohexol injection, particularly at low GFR.
It is likely that the two- or four-point plasma disappearance
of iohexol will be utilized as a standard measure of GFR
in situations in which estimates of GFR are likely to be
imprecise, as well as in clinical trials and observational
studies of chronic kidney disease.
MATERIALS AND METHODS
Subjects
Twenty-nine subjects, including 27 children and two adults, were
consented. Each ingested a low-protein diet (19 and 34 g/day for
4–8- and 9–13-year-olds, respectively) on the day before study and
no food after midnight. The study was approved by the Research
Study Review Boards of the University of Rochester and Johns
Hopkins School of Medicine. Fifteen subjects were studied in the
General Clinical Research Center of the University of Rochester
School of Medicine and 14 in the Pediatric Clinical Research Unit of
the Johns Hopkins School of Medicine. At the visit, height, weight,
and vital signs were determined, a fluid load of 5 ml/kg given, and
two intravenous lines placed, one for blood sampling and one for
the iohexol bolus administration. Demographic data showing
medians and the first and third quartiles are shown in Table 1.
The status of the 27 pediatric subjects at the time of study included
12 with obstructive uropathy-dysplasia, four with kidney trans-
plants, four with chronic glomerulonephrits, and seven with other
diseases (including hereditary and cystic kidney disease).
Studies and assays
Before study and as standard of care, blood was obtained for serum
creatinine determination; an aliquot was also obtained for HPLC
analysis to determine if there were any detectable peak before
iohexol infusion. At the University of Rochester, creatinine was
determined enzymatically using a Vitros 950 (Ortho Clinical
Diagnostics, Rochester, NY, USA) or an Advia 2400 (Bayer
Diagnostics, Tarrytown NY, USA) analyzer. At Johns Hopkins,
creatinine was determined in 10 of 14 subjects by enzymatic assay
(Roche Hitachi Modular P800 (Holliston, MA, USA) and in four by
a Jaffe colorimetric assay. Iohexol (5 ml; GE Healthcare, Amersham
Division, Princeton, NJ, USA) was administered from a pre-weighed
syringe beginning at time zero over a period of 1–2 min. The syringe
was then weighed to the nearest tenth gram on the same scale used
before the injection. The dose of iohexol (I, in mg) was calculated
from the difference in syringe weights multiplied by the concentra-
tion of iohexol (647 mg/ml) divided by its density at room
temperature (1.345). The median dose of iohexol was 3185 mg
(Table 1). Vital signs were taken 10 min after completing the
infusion to assure that there were no untoward reactions by the
subjects. One subject with shell-fish allergy was given prednisone
and diphenhydramine before study. This subject had no allergic
reaction to the iohexol. One child had some nausea and vomited
once 5 h after the infusion. None of the other 28 subjects had any
significant adverse reaction to iohexol.
Blood samples (1 ml) were obtained at 5, 10, 20, 30, 60, 120, 180,
240, 300, and 360 min after starting the iohexol injection. Each
sample was placed into a serum separator tube, inverted 5–10 times,
and allowed to stand for 30 min, before being centrifuged at 1100 g
Kidney International (2006) 69, 2070–2077 2075
GJ Schwartz et al.: Iohexol plasma disappearance GFR in children o r i g i n a l a r t i c l e
for 10 min. The sera obtained were deproteinated by the addition of
four volumes of 5% perchloric acid, followed by centrifugation. The
HPLC analysis of the supernatant was carried out on an Agilent
1100 HPLC system with variable wavelength ultraviolet detector and
a Zorbax Eclipse XBD-C8 4.6 150 mm, 5 mm particle size column.
The chromatographic conditions included an injection volume of
25 ml, isocratic elution at 1 ml/min with 20 mM potassium phosphate
pH 2.5 and 4% acetonitrile; the column was maintained at 301C,
peaks were monitored at 254 nm. The second and larger of the two
iohexol peaks, eluting at B4 min, was used for determination of
iohexol concentration (mg/l). Standards were prepared by diluting
injectable iohexol in sheep serum. Initial tests adding iohexol to the
sera of kidney transplant patients (taking at least 10 different
medications) did not show significant losses in iohexol recovery (not
shown). In all 29 studies, there was no detectable peak atB4 min in
the blood samples taken before iohexol infusion, indicating no
interference with the assay.
After completion of the iohexol bolus, subjects were asked to
provide a ‘discard’ urine sample. The time of this discard was taken
to be the beginning of the first urine collection. The volume of the
discard was measured and the subjects were asked to drink the
equivalent volume of fluids. Four collections of urine were then
obtained following this format. Volumes were measured to the
nearest 5 ml.
Calculations
Two-compartment model. Following the approach of Sapirst-
ein37 the disappearance of a glomerular marker can be resolved into
two curves using the logarithm of the concentration of iohexol as a
function of time. The slow (renal) curve was determined from the
concentrations obtained at 120–360 min. The fast curve was
determined from 10 to 60 min concentrations. Because the iohexol
concentrations at the 5 min point were frequently less than those at
10 min (reflecting ongoing equilibration), the 5 min data were not
utilized in any analysis and GFR was determined from the remaining
nine points (GFR(9)).
GFR was calculated from
GFR ¼ I=ðexpA=aþ expB=bÞ1:73=BSA; in ml=min per 1:73m2
where I is the dose of iohexol (mg), exp A is the intercept of the slow
curve, and a its corresponding slope, exp B the intercept of the fast
curve, and b its corresponding slope; GFR was corrected to 1.73 m2
body surface area (BSA) by the ratio 1.73/BSA.
Body surface area. Values of BSA were determined from the
subject’s height and weight using the formula of Haycock et al.:38
BSAðm2Þ ¼ 0:024265Wt0:5378Ht0:3964
where Wt is the subject’s weight in kg and Ht the height in cm.
To reduce the number of necessary serum samples in preparation
for the nation-wide study, we compared a four-point GFR
(GFR(4)), comprised of the samples taken at 10, 30, 120, and
300 min against GFR(9). These samples are the minimum required
to determine both the slow curve (120 and 300 min) and the fast
curve (10 and 30 min).
One-compartment model. The one-compartment model is
predicated on the observation that most of the GFR can be
approximated by the slow (A, a) curve. Consistent with the
observation of Brochner-Mortensen,19
GFR ¼ C1GFRðAÞ þ C2ðGFRðAÞÞ2
where GFR(A)¼ (I/(exp A/a)) 1.73/BSA. and C1 and C2 are
constants determined empirically by curve-fitting against the two-
compartment GFR. Specifically, to determine C1 and C2, we
regressed GFR(9) on GFR(A) based only on the slow curve from
the five concentrations obtained at 120–360 min.
To explore the possibility that only two points may suffice to
measure GFR, we compared a two-point GFR (GFR(2)), comprised
of the samples taken only at 120 and 300 min, to characterize the
slow curve and used it in the Brochner-Mortensen-like equation19 to
calculate the GFR. Specifically,
GFRð2Þ ¼ C1GFRðaÞ þ C2ðGFRðaÞÞ2
where GFR(a) is the GFR of the slow curve derived from the
concentrations at 120 and 300 min.
Estimated GFR. The eGFR was calculated from:
eGFR ¼ kHt=Scr; in ml= min per 1:73m2
where k¼ 0.55, except in males above 13-years old (k¼ 0.7),2,39 Ht
(height) in cm, and Scr is serum creatinine in mg/dl. This formula is
not valid in adults and hence was not used for the two adult
subjects.
Renal clearance of iohexol (GFRi). The standard renal
clearance equation was used to calculate GFRi and the four data
points were averaged as a geometric mean for each subject:
GFRi ¼ UiVi=Si
where Ui is the iohexol concentration in the ith urine sample, Vi is
the urine volume of the ith urine sample, and Si is the area under the
serum iohexol disappearance curve while urine is being collected for
the ith clearance.
Statistics
Nonparametric statistics (e.g., medians and quartiles) were used
to describe the demographics of the study population and the
components of the calculations of GFRs.
To describe the agreement between two variables Y (e.g., GFR(9))
and X (e.g., GFR(4)), we depicted the standard plot of X vs Y and the
corresponding Bland–Altman40 plot of the average of X and Y vs
the difference of X from Y. The slope of the linear regression of the
difference (XY) on the average ((XþY)/2) from the Bland–Altman
plot is directly related to the ratio of the s.d. of X and Y (i.e., the s.d.
of X and Y are equal if and only if the slope is zero), and the residual
variance is directly related to the correlation between X and Y. The
mean of the differences between the two tests is referred to as bias.
Testing the null hypothesis of no bias (i.e., mean difference¼ 0) is
accomplished by application of the paired t-test. The testing of no
bias and equality of s.d. can be accomplished in a unified analysis by
centering (Xþ Y)/2 around its mean and performing the regression
as indicated above.
Standard regression methods for Gaussian data were used to
derive the estimates of the coefficients of the Brochner-Mortensen
equation,19 which amounts to a quadratic regression model with no
intercept with GFR(9) as the dependent variable and both GFR(A)
and the square of GFR(A) as the independent variables.
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